Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer
Status:
Withdrawn
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the efficacy of varlitinib in combination with
capecitabine as measured by objective response rate (ORR) assessed by independent central
review (ICR), based on RECIST v1.1 criteria.